BusinessPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent DevelopmentsBy Nasdaq OMXJul 14, 2017, 8:13 PM UTC
BusinessPeregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017By Nasdaq OMXJul 7, 2017, 8:05 PM UTC
BusinessSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe GoutBy Nasdaq OMXJun 15, 2017, 11:30 AM UTC
BusinessCell Design Labs Announces Issuance of Broad Patent for Chimeric Notch (synNotch™) Receptor to Treat Cancer and Other DiseasesBy Nasdaq OMXJun 7, 2017, 12:00 PM UTC
BusinessJounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual MeetingBy Nasdaq OMXMay 17, 2017, 9:00 PM UTC
BusinessSelecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)By Nasdaq OMXMay 15, 2017, 12:02 PM UTC
BusinessSelecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)By Nasdaq OMXMay 15, 2017, 12:02 PM UTC
